Navigation Links
New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia
Date:12/13/2007

Solstice Neurosciences, Inc. Launches a Self-Guided Lesson as Prep for

In-Person Workshops

MALVERN, Pa., Dec. 13 /PRNewswire/ -- In recognition that physician comfort and knowledge with techniques around botulinum toxin injections lead to the best results for patients with cervical dystonia (CD), Solstice Neurosciences, Inc. (Solstice) has created MYOBLOC(TM) University, an online, self-study resource that incorporates new learning technology. The course integrates multi-dimensional, life-like animation throughout the content -- with anatomy based on real patients with CD and actual injection technique demonstrations with Myobloc(R) (Botulinum Toxin Type B) Injectable Solution. The course can be accessed at http://www.myoblocuniversity.com.

"MYOBLOC(TM) University is for busy physician specialists who want to expand the scope of treatment options for their patients with cervical dystonia, and for those seeking a comprehensive review of the condition and the role of botulinum toxin type B," said Eric J. Pappert, MD, assistant professor of neurology and director of the Parkinson's Disease and Movement Disorders Program at the University of Texas Health Science Center in San Antonio, Texas and Vice President, Medical & Scientific Affairs of Solstice. Dr. Pappert led the development of MYOBLOC(TM) University.

CD is often a disabling and painful movement disorder that requires life- long management. Also known as spasmodic torticollis, it is a condition that primarily affects the cervical area of the neck. While the exact cause of CD is unknown, scientists believe the problem originates in the basal ganglia area of the brain that is instrumental in movement. The treatment goal is to lessen symptoms of spasms, pain and impaired posture, and to improve functionality.

"A broad range of treatment options are often needed to address the symptoms of cervical dystonia. The botulinum toxins are considered the primary and most effective form of treatment, which makes it critically important for physicians to be experienced with both forms of botulinum toxin available here in the U.S.," noted Dr. Pappert.
The multi-media content covered in MYOBLOC(TM) University includes:

-- Detailed overview of the clinical presentation and diagnosis of CD --

with video depictions demonstrating abnormal movements and which muscle

are involved

-- Review of currently available treatments -- oral medications, surgical

options, injections with botulinum toxin, and complementary therapies

-- Fundamentals for dosing and muscle injection techniques when using

MYOBLOC to reduce the severity of abnormal head position and neck pain

associated with CD

-- Patient case studies that illustrate the challenges and potential

solutions in managing CD patients

-- A post-test for participants to gauge their understanding of the

materials presented

Upon completing the online lesson, physicians can request in-person training with MYOBLOC, which is available through Solstice in a variety of venues. The company's overall goal is to support physicians who care for CD patients -- ranging from neurologists to physiatrists to anesthesiologists and pain management physicians.

MYOBLOC(TM) University does not offer continuing medical education credits.

About MYOBLOC

Myobloc(R) (Botulinum Toxin Type B) Injectable Solution is indicated for the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.

Before administering MYOBLOC, physicians should consult the full Prescribing Information.

The most frequently reported adverse events with MYOBLOC are dry mouth, dysphagia, dyspepsia, and injection site pain. These adverse events are generally mild to moderate, transient, self-resolving, and more common with higher doses.

For full Prescribing Information, please visit http://www.myobloc.com.

About Solstice Neurosciences, Inc.

Founded in 2004, Solstice Neurosciences, Inc. is a biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty products. Solstice's first product, MYOBLOC, represents the only botulinum toxin type B currently available to physicians and patients. MYOBLOC is sold in the United States and approved in Canada. It is also distributed and sold in the EU as NeuroBloc. MYOBLOC is indicated for the treatment of patients with cervical dystonia (CD) to reduce the severity of abnormal head position and pain associated with CD. For more information about Solstice Neurosciences, Inc., visit http://www.solsticeneuro.com

Myobloc(R) and NeuroBloc(R) are registered trademarks of Solstice Neurosciences, Inc.

Editor's Note: for access to current course offerings, users must register on website; users can access site regardless of medical credentials.


'/>"/>
SOURCE Solstice Neurosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Social Network for Scientists Marks Ten Years Online
2. BioReliance Corporation Launches iNet(TM) for Online Results Tracking of Biological Safety Tests
3. K-State Research Leading to Software to Help Nations Cattle Producers Identify Biosecurity Risks, Evaluate Impact of Cow-Calf Diseases Online
4. Bio Career Center Launches First Online Jobs Board for Life Science PhDs, MDs
5. New Online Help Desk Offers Safe Lifting Assistance to Healthcare Facilities
6. MIT: Leveraging learning for artificial respiration
7. MIT: Leveraging learning for artificial respiration
8. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
9. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
10. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
11. New designer toxins kill Bt-resistant insect pests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , ... announced today the Clinical Reach Virtual Patient Encounter CONSULT module which enables ... the physician and clinical trial team. , Using the CONSULT module, patients and physicians ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
Breaking Biology News(10 mins):